Story perspectives
CRISPR Boosts CAR T Therapy, Targets Leukemia Successfully
9/25/2025
50 7
1 of 1
Story summary
- CELLFIE, developed by CeMM and the Medical University of Vienna, uses CRISPR to enhance CAR T therapy.
- RHOG is identified as a key target, with leukemia clearance in preclinical models.
- Dual RHOG and FAS knockouts show synergistic anti-tumor activity and increased survival in mice.
- Long-term safety data show no adverse events from gene editing, including solid tumors as potential beneficiaries.
